

# Gwenaël Ferron

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6484689/publications.pdf>

Version: 2024-02-01

55  
papers

1,966  
citations

394421

19  
h-index

243625

44  
g-index

58  
all docs

58  
docs citations

58  
times ranked

2235  
citing authors

#	ARTICLE	IF	CITATIONS
1	Complete Cytoreductive Surgery Plus Intraperitoneal Chemohyperthermia With Oxaliplatin for Peritoneal Carcinomatosis of Colorectal Origin. <i>Journal of Clinical Oncology</i> , 2009, 27, 681-685.	1.6	758
2	Audit of preoperative and early complications of laparoscopic lymph node dissection in 1000 gynecologic cancer patients. <i>American Journal of Obstetrics and Gynecology</i> , 2006, 195, 1287-1292.	1.3	126
3	Maximal Cytoreduction in Patients With FIGO Stage IIIC to Stage IV Ovarian, Fallopian, and Peritoneal Cancer in Day-to-Day Practice: A Retrospective French Multicentric Study. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 1337-1343.	2.5	89
4	Pharmacokinetics of Oxaliplatin During Open Versus Laparoscopically Assisted Heated Intraoperative Intraperitoneal Chemotherapy (HIPEC): An Experimental Study. <i>Annals of Surgical Oncology</i> , 2008, 15, 339-344.	1.5	73
5	PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells. <i>JCI Insight</i> , 2021, 6, .	5.0	64
6	Multi-Center Evaluation of Post-Operative Morbidity and Mortality after Optimal Cytoreductive Surgery for Advanced Ovarian Cancer. <i>PLoS ONE</i> , 2012, 7, e39415.	2.5	64
7	Survival Benefit of Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer: A Multi-institutional Case Control Study. <i>Annals of Surgical Oncology</i> , 2014, 21, 3621-3627.	1.5	47
8	Tumor cells educate mesenchymal stromal cells to release chemoprotective and immunomodulatory factors. <i>Journal of Molecular Cell Biology</i> , 2020, 12, 202-215.	3.3	47
9	CA-125 ELIMINATION Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial. <i>Clinical Cancer Research</i> , 2020, 26, 4625-4632.	7.0	47
10	Oxaliplatin-based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: A pilot study of 31 patients. <i>Journal of Surgical Oncology</i> , 2011, 103, 10-16.	1.7	46
11	Should Systematic Infra-renal Para-aortic Dissection Be the Rule in the Pretherapeutic Staging of Primary or Recurrent Locally Advanced Cervix Cancer Patients With a Negative Preoperative Para-aortic PET Imaging?. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 169-175.	2.5	42
12	Feasibility of laparoscopic peritonectomy followed by intra-peritoneal chemohyperthermia: An experimental study. <i>Gynecologic Oncology</i> , 2005, 99, 358-361.	1.4	41
13	Increased Tissue Diffusion of Oxaliplatin During Laparoscopically Assisted Versus Open Heated Intraoperative Intraperitoneal Chemotherapy (HIPEC). <i>Annals of Surgical Oncology</i> , 2008, 15, 3623-3624.	1.5	40
14	Laparoscopy-assisted vaginal pelvic exenteration. <i>Gynecologic Oncology</i> , 2006, 100, 551-555.	1.4	36
15	Pelvic lymph node dissection via a lateral extraperitoneal approach: Description of a technique. <i>Gynecologic Oncology</i> , 2008, 109, 81-85.	1.4	26
16	Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: guidelines from the French national network dedicated to rare gynaecological cancers. <i>European Journal of Cancer</i> , 2019, 116, 35-44.	2.8	25
17	Cost-Effectiveness of Intraperitoneal Chemohyperthermia in the Treatment of Peritoneal Carcinomatosis from Colorectal Cancer. <i>Value in Health</i> , 2008, 11, 347-353.	0.3	24
18	Fertility and prognosis of borderline ovarian tumor after conservative management: Results of the multicentric OPTIBOT study by the GINECO & TMRG group. <i>Gynecologic Oncology</i> , 2020, 157, 29-35.	1.4	24

#	ARTICLE	IF	CITATIONS
19	Vaginal reconstruction with pedicled vertical deep inferior epigastric perforator flap (diep) after pelvic exenteration. A consecutive case series. <i>Gynecologic Oncology</i> , 2015, 138, 603-608.	1.4	22
20	Gene expression analysis of matched ovarian primary tumors and peritoneal metastasis. <i>Journal of Translational Medicine</i> , 2012, 10, 121.	4.4	21
21	Creation of the Miami Pouch During Laparoscopic-Assisted Pelvic Exenteration: The Initial Experience. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 466-470.	2.5	20
22	Evaluation of the effects of hyaluronic acid-carboxymethyl cellulose barrier on ovarian tumor progression. <i>Journal of Ovarian Research</i> , 2014, 7, 40.	3.0	20
23	Laparoscopic staging of early ovarian carcinoma. <i>Current Opinion in Obstetrics and Gynecology</i> , 2006, 18, 407-412.	2.0	19
24	Prognostic Relevance of Celiac Lymph Node Involvement in Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 48-53.	2.5	19
25	Urinary diversion after pelvic exenteration for gynecologic malignancies. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1-10.	2.5	17
26	Dual Relief of T-lymphocyte Proliferation and Effector Function Underlies Response to PD-1 Blockade in Epithelial Malignancies. <i>Cancer Immunology Research</i> , 2020, 8, 869-882.	3.4	16
27	The impact of pleural disease on the management of advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 138, 216-220.	1.4	13
28	A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 158, 614-621.	1.4	13
29	Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC) patients: The CHIVA double-blind randomized phase II GINECO study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5512-5512.	1.6	13
30	Preferential Allele Expression Analysis Identifies Shared Germline and Somatic Driver Genes in Advanced Ovarian Cancer. <i>PLoS Genetics</i> , 2016, 12, e1005755.	3.5	12
31	When and Who Should Perform Epithelial Ovarian Cancer Surgery?. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 594-599.	2.5	12
32	Novel Surgical Strategies in the Treatment of Gynecological Malignancies. <i>Current Treatment Options in Oncology</i> , 2018, 19, 73.	3.0	12
33	Laparoscopic Management of an Isolated Ovarian Metastasis on a Transposed Ovary in a Patient Treated for Stage IB1 Adenocarcinoma of the Cervix. <i>Journal of Minimally Invasive Gynecology</i> , 2009, 16, 106-108.	0.6	11
34	Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study). <i>Gynecologic Oncology</i> , 2020, 159, 256-263.	1.4	11
35	Laparoscopic anterior pelvic exenteration in 10 steps. <i>Gynecologic Oncology</i> , 2018, 150, 201-202.	1.4	10
36	Comparison of postoperative complications and quality of life between patients undergoing continent versus non-continent urinary diversion after pelvic exenteration for gynecologic malignancies. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 233-240.	2.5	10

#	ARTICLE	IF	CITATIONS
37	Predicting tumor response and outcome of second-look surgery with 18F-FDG PET/CT: insights from the GINECO CHIVA phase II trial of neoadjuvant chemotherapy plus nintedanib in stage IIIc-IV FIGO ovarian cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1998-2008.	6.4	9
38	Are Early Relapses in Advanced-Stage Ovarian Cancer Doomed to a Poor Prognosis?. <i>PLoS ONE</i> , 2016, 11, e0147787.	2.5	7
39	Treatment of neovaginal prolapse: case report and systematic review of the literature. <i>International Urogynecology Journal</i> , 2017, 28, 41-47.	1.4	7
40	Prognostic impact of celiac lymph node involvement in patients after frontline treatment for advanced ovarian cancer. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1410-1416.	1.0	7
41	Development of a near infrared protein nanoprobe targeting Thomsen-Friedenreich antigen for intraoperative detection of submillimeter nodules in an ovarian peritoneal carcinomatosis mouse model. <i>Biomaterials</i> , 2020, 241, 119908.	11.4	7
42	First Laparoscopic Repair of Neovaginal Prolapse Following Ileocecal Reconstruction After Resection of Vaginal Carcinoma. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2009, 19, 67-69.	1.0	6
43	How should we stage and tailor treatment strategy in locally advanced cervical cancer? Imaging versus para-aortic surgical staging. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1434-1443.	2.5	6
44	Creation of a Miami Pouch in 10 logical steps. <i>Gynecologic Oncology</i> , 2018, 151, 178-179.	1.4	4
45	Laparoscopic hand-assisted Miami Pouch after pelvic exenteration in 10 steps. <i>Gynecologic Oncology</i> , 2018, 150, 389-390.	1.4	4
46	Randomized Study of Aggressive Surgery for Advanced Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 1168.2-1170.	2.5	3
47	Which Surgical Attitude to Choose in the Context of Non-Resectability of Ovarian Carcinomatosis: Beyond Gross Residual Disease Considerations. <i>Annals of Surgical Oncology</i> , 2016, 23, 434-442.	1.5	3
48	Left Lateral Endosurgical Extraperitoneal Total Hysterectomy with Para-Aortic and Pelvic Lymphadenectomy: A Novel Approach for the Obese Patient with Endometrial Cancer. <i>Journal of Minimally Invasive Gynecology</i> , 2018, 25, 730-736.	0.6	3
49	Laparoscopic observation of the diaphragm undersurface in the staging of peritoneal carcinomatosis: comparison of three optical systems. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2012, 164, 65-68.	1.1	2
50	Vaginal reconstruction after pelvic exenteration with a vertical deep inferior epigastric perforator flap in 10 steps. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 2015-2016.	2.5	2
51	Survival Outcomes after Hyperthermic Intraperitoneal Chemotherapy for a First Ovarian Cancer Relapse: A Systematic Evidence-Based Review. <i>Cancers</i> , 2022, 14, 172.	3.7	2
52	Aortic abdominal dissection after retroperitoneal laparoscopic paraaortic lymphadenectomy. <i>Gynecologic Oncology Reports</i> , 2019, 29, 25-28.	0.6	1
53	Laparoscopically Assisted Heated Intra-Operative Intraperitoneal Chemotherapy (HIPEC): Technical Aspect and Pharmacokinetics Data. , 2009, , 343-351.		1
54	Complications and Management of Radical Cytoreduction. , 2018, , 182-191.		0

#	ARTICLE	IF	CITATIONS
55	Fertility sparing technique during pelvic exenteration for recurrent vaginal rhabdomyosarcoma. Journal of Pediatric Surgery Case Reports, 2018, 38, 23-26.	0.2	0